新時代のがん個別化医療につながる治療標的を探索し、がん制圧の未来へ

Searching for Therapeutic Targets Leading to a New Era of Personalized Cancer Care and a Future of Cancer Control

 

 

 

 

 

 

 
We will analyze tumor tissue, stool, and blood samples from cancer patients collected in the biobank at Tohoku University Hospital to discover bacteria and their metabolites that enhance the effects of anticancer drugs and reduce side effects.

 

The following studies are currently underway to achieve the goal.

 

 

We will focus on gastrointestinal cancers (esophageal, gastric, colorectal, pancreatic, biliary tract, etc.), head and neck, and sarcomas. Still, we will not specify the type of cancer by organ and conduct research to apply to cancers across organs.

 

Our goal is to utilize your donations for these studies and use the results to improve treatment outcomes for advanced cancer.

 

Even if the total amount of donations does not reach the target amount by the deadline, we will make up the difference by providing research grants to cover the difference and carry out the abovementioned activities.

 

*The implementation plan for the above clinical research has been reviewed and approved by the Ethics Committee of Tohoku University Graduate School of Medicine. The implementation of this project is scheduled to be completed by the end of March 2028.

 

Research Organization: Chikashi Ishioka, Masanobu Takahashi, Hidekazu Shirota, Hiroo Imai, Kota Ouchi (these 5 researchers are M.D. and Ph. D. at Department of Clinical Oncology, Tohoku University Graduate School of Medicine and Department of Medical Oncology, Tohoku University Hospital), and Toru Ishikawa (Manager of these office)

 

 

 

In recent years, personalized medicine has been developed. Each patient's constitution, type of disease, and type of the disease are examined in detail, and treatment is determined according to the results.

 

In particular, research on personalized medicine is progressing in cancer treatment, where genome analysis is being conducted to obtain information at the genetic level, which is then used in actual clinical practice.

 

Personalized medicine is already in place in which genetic mutations and molecular abnormalities of cancer cells are investigated, and anticancer drugs are determined for them. However, there is still plenty of room for development in personalized medicine. As an essential theme for Japan, it is an area where the further promotion of research and enhancement of the system is needed.

 

 

In the future, personalized medicine will be further researched. Research results will be obtained based on not only gene mutation analysis of cancer cells but also a more detailed analysis of genes and proteins, analysis of factors involved in the protein synthesis process, and comprehensive analysis of data (omics analysis) on metabolites produced by bacteria parasitic on the human body, etc. The results of our research will be obtained based on a comprehensive analysis of data (omics analysis).

 

From this, we can expect to make many discoveries that will benefit patients in cancer treatment, such as the development of highly effective anticancer drugs, the development of combination drugs that enhance the effects of anticancer drugs, and the development of new treatment methods that alleviate the side effects of anticancer drugs.

 

 
Your donation to this project will be considered a donation to Tohoku University and eligible for tax benefits.

*Only Japanese taxpayers are eligible for this program, and overseas taxpayers do not qualify for preferential treatment.

 

■Income Taxes (Earned Income Tax Credit)
Income tax deductions are available for donations exceeding 2,000 yen per year.

Amount of donation - 2,000 yen = income deduction

(The maximum amount of donations that can be deducted is 40% of gross income for the year in question.)

 

■Resident Tax
Donors residing in Miyagi Prefecture and municipalities (Sendai, Tagajo, Ishinomaki, Tomiya, Watari, and Onagawa) that have designated the University as a "corporation, etc., eligible for a donation tax credit" are entitled to a reduction in their inhabitant tax for the following year, in addition to the income tax credit.

(Amount of donation - 2,000 yen) x 4-10% = Resident tax credit

(The maximum amount of donations that can be deducted is 30% of gross income for the relevant year.)

*For 4-10% of the above formula
Donations designated by prefectures: 4%.
Donations designated by the municipality are 6%.
(10% for donations designated by both the prefecture and the municipality)

*Sendai City residents will receive a 2% prefectural inhabitant tax credit and an 8% municipal inhabitant tax credit. The total deduction percentage is 10%, the same as for residents of other eligible municipalities.

The total amount of the donation is deductible for tax purposes.

A "Certificate of Donation Receipt" will be sent to donors later.

The name on the donation receipt will be registered for the gift recipient.

Please note that a certificate of receipt is required for tax returns with your real name and current address (the address shown on your resident registration certificate), or in the case of a corporation, with your registered name and address.

(It is expected to be sent by the end of September 2023. The date of the donation receipt certificate will be the date of August 2023, when the payment is received from READYFOR to Tohoku University).

 

*We would like to make your donation to this project eligible for an award from the "Tohoku University Fund.”Please note that the Tohoku University Foundation may contact you shortly regarding issuing a certificate of receipt for your donation, the publication of your name on the certificate, and the award details. Please note that the Tohoku University Fund may contact you shortly.

 

If you have difficulty donating online,

Please get in touch with us at the contact information below.

Tohoku University Fund Office
E-mail:kikin@grp.tohoku.ac.jp
tel: 022-217-5058/5905
 

About this Study

This crowdfunding campaign requests donations for "the search for novel diagnostic methods and novel therapeutic targets for personalized medicine" and the maintenance of related research and research systems. In various analyses, we only sometimes obtain the expected results.

 

About Crowdfunding

Please note that regardless of whether or not the target amount is reached, the application for this project is confirmed once the donation is made and cannot be canceled afterward.

 

Messages received as "supportive comments" upon completion of the donation may be used to promote the acquisition of gifts for this project.

When you donate by bank transfer, we will ask you for your bank account information, but in principle, no refunds will be made due to our all-in policy. However, in the unlikely event that we cannot implement a project that we have introduced or promised on this website, or if the amount transferred exceeds the amount reserved or is insufficient to cover the additional amount to be transferred, we will use the bank account information for refunds. Please take a few minutes to fill out the form.

 

For details on the terms and conditions of this project's gift regarding [name listing], please refer to the link (https://readyfor.jp/terms_of_service#appendix) under "Support Agreement" under "Naming Rights, Message Listing, and Other Similar Returns" Please refer to to to to the "Support Agreement" at the following link () for details on the conditions for [Name Listing] gifts.
 
Handling of Personal Information

Tohoku University may send you reports and donation information (by mail, e-mail, etc.) in the future. If you do not wish to receive such information, please specify so during the crowdfunding donation process.

 

Contact: Department of Clinical Oncology, Tohoku University Graduate School of Medicine

E-mail address: toruishi@t-core.jp (Ishikawa)

 

*If you have difficulty donating online, please get in touch with us at the contact information below.

Contact: Tohoku University Fund Office

E-mail address: kikin@grp.tohoku.ac.jp

Phone number: 022-217-5058/5905

Project Execution Manager:
Chikashi Ishioka (Department of Oncology, Tohoku University Hospital, Tohoku University)
Date of completion of project implementation:　March 31, 2028
Project Summary and Use of Funds Raised
Conduct clinical research on anticancer drug therapy and search for recent and candidate molecules that affect therapeutic efficacy by comprehensive molecular analysis (genomic, epigenomic, microbiome, metabolomic, etc.) of specimens (tumor, stool, and blood) collected from patients participating in clinical research. In addition, basic experiments will be conducted to verify the effect-enhancing mechanisms of candidate bacteria and molecules. Donations will be used for research expenses to conduct clinical research aimed at developing new treatments through genome analysis and other comprehensive molecular analysis, as well as personnel expenses for researchers and administrative staff working on this research project.
 
Profile
Chikashi Ishioka is one of Japan's first JSMO board certified-medical oncologists and has been the Professor of Medical Oncology at the Tohoku University Hospital since 2003. Chikashi Ishioka is one of Japan's first JSMO board certified-medical oncologists and has been the Professor of Medical Oncology at the Tohoku University Hospital since 2003. 

He has also been the Director of the Cancer Center (since 2012), the Director of the Personalized Medicine Center (since 2017) and the Vice President (Has also been the Director of the Cancer Center (since 2012), the Director of the Personalized Medicine Center (since 2017) and the Vice President ( since 2015) of the Tohoku University Hospital, and contributed for promotion of cancer research and personalized medicine, development of the local cancer medical care as Representative Director of the Tohoku Clinical Oncology Research and Education Society (T-CORE, sine 2004) and the Administration Committee of the Tohoku Cancer Network (since 2008). Also, he has contributed to the training of the cancer medical care specialists such as medical oncologists through the activities as the Coordinator of the Also, he has contributed to the movement of the cancer medical care specialists such as medical oncologists through the activities as the Coordinator of the Tohoku Cancer Professional Training Promotion Plan (supportive by the MEXT Japan, since 2007).

He obtained an MD from the Tohoku University School of Medicine in 1984 and a Ph.D. (Doctor of Medical Science) from the Tohoku University Postgraduate School of Medicine in 1988. After clinical training in gastrointestinal and hematological oncology at Tohoku University and the associated hospitals, he studied molecular cancer genetics, TP53 function, and hereditary cancer as a genetic approach. After clinical training in gastrointestinal and hematological oncology at Tohoku University and the associated hospitals, he studied molecular cancer genetics, TP53 function, and hereditary cancer as a Research Associate in Dr. Stephen Friend's lab at the Cancer Center. Stephen Friend's lab at the Cancer Center of the Massachusetts General Hospital (MGH) and Harvard Medical School from 1992 to 1994.

He established a lot of functional assays of the cancer-related genes, including TP53, PTEN, MLH1, and BRCA1 genes. He evaluated the pathogenic significance of the missense mutations by using yeast and mammalian cells (Ishioka C et al. He established a lot of functional assays of the cancer-related genes, including TP53, PTEN, MLH1, and BRCA1 genes. He evaluated the pathogenic significance of the missense mutations using yeast and mammalian cells (Ishioka C et al. PNAS 1997, Krainer M et al. NEJM 1997, Shimodaira H et al. Nat Genet 1998, Osada M et al. Nat Med 1998, Nichols KE et al.) The achievements were adopted for the international database, such as the UMD TP53 database (Hamroun D et al. Hum Mut 2006) and the IARC TP53 mutation database (Petitjean A et al. The achievements were adopted for the international database such as the UMD TP53 database (Hamroun D et al. Hum Mut 2006) and the IARC TP53 mutation database (Petitjean A et al. Hum Mut 2007) and utilized for extensive international collaborative clinical studies (Iacopetta B at al. Clin Cancer Res 2006). He organized a lot of international collaborative studies with Dr. Richard D Kolodnar (UC San Diego), Dr. Daniel A Haber (MGH), and other scientists.

He has played essential roles in Japan's significant academic societies of oncology. Since 2019, he has been the President of the Japanese Society of Medical Oncology (JSMO). He was also the Director of the Japanese Society of Clinical Oncology (JSCO) from 2010 to 2013 and the Director of the Japanese Cancer Association (JCA) from 2015 to 2017. He has served on the editorial board of the Cancer Science and the International Journal of Clinical Oncology for an extended period.

His main research interests include chemotherapy for gastrointestinal cancer and other cancers and translational research such as the development of Recently, his research group has identified the genome-wide DNA methylation status is the predictive marker of anti-EGFR treatment in metastatic colorectal cancer (Ouchi K et al. Cancer Science 2015). His research group has also identified the novel synthesized depsipeptides as HDAC/PI3K dual inhibitors (Saijo K et al. Cancer Science 2012). It has Cancer Science 2012) and has worked on developing one of the newly synthesized inhibitors as a novel molecular target drug supported by AMED Japan (Saijo K et al. Science 2015).